Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
Background Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC).Methods 125 consecutive patients with aLCNEC were identified in the electronic databases of 4 participating cancer centers. The patients...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/2/e001999.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557852300935168 |
|---|---|
| author | Samuel Kareff Jair Bar Amir Onn Alona Zer Chul Kim Stephen V Liu Elizabeth Dudnik Mor Moskovitz Anastasiya Lobachov Teodor Gottfried Damien Urban Ofer Rotem Mira Wollner |
| author_facet | Samuel Kareff Jair Bar Amir Onn Alona Zer Chul Kim Stephen V Liu Elizabeth Dudnik Mor Moskovitz Anastasiya Lobachov Teodor Gottfried Damien Urban Ofer Rotem Mira Wollner |
| author_sort | Samuel Kareff |
| collection | DOAJ |
| description | Background Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC).Methods 125 consecutive patients with aLCNEC were identified in the electronic databases of 4 participating cancer centers. The patients were divided into group A (patients who received ICI, n=41) and group B (patients who did not receive ICI, n=84). Overall survival since advanced disease diagnosis (OS DX) and OS since ICI initiation (OS ICI) were captured.Results With a median follow-up of 11.8 months (mo) (IQR 7.5–17.9) and 6.0mo (IQR 3.1–10.9), 66% and 76% of patients died in groups A and B, respectively. Median OS DX was 12.4mo (95% CI 10.7 to 23.4) and 6.0mo (95% CI 4.7 to 9.4) in groups A and B, respectively (log-rank test, p=0.02). For ICI administration, HR for OS DX was 0.59 (95% CI 0.38 to 0.93, p=0.02—unadjusted), and 0.58 (95% CI 0.34 to 0.98, p=0.04—adjusted for age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), presence of liver metastases and chemotherapy administration). In a propensity score matching analysis (n=74; 37 patients in each group matched for age and ECOG PS), median OS DX was 12.5 mo (95% CI 10.6 to 25.2) and 8.4 mo (95% CI 5.4 to 16.9) in matched groups A and B, respectively (log-rank test, p=0.046). OS ICI for patients receiving ICI as monotherapy (n=36) was 11.0 mo (95% CI 6.1 to 19.4).Conclusions With the limitations of retrospective design and small sample size, the results of this real-world cohort analysis suggest a positive impact of ICI on OS in aLCNEC. |
| format | Article |
| id | doaj-art-b4a8ed4bacae4a4eb4687cec2aca3a89 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2021-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-b4a8ed4bacae4a4eb4687cec2aca3a892025-02-03T02:05:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-02-019210.1136/jitc-2020-001999Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungSamuel Kareff0Jair Bar1Amir Onn2Alona Zer3Chul Kim4Stephen V Liu5Elizabeth Dudnik6Mor Moskovitz7Anastasiya Lobachov8Teodor Gottfried9Damien Urban10Ofer Rotem11Mira Wollner12Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA2 Thoracic Oncology Unit, Institute of Oncology, Tel HaShomer Hospital, Tel Hashomer, Israel2 Thoracic Oncology Unit, Institute of Oncology, Tel HaShomer Hospital, Tel Hashomer, IsraelSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelLombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA3Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USAThoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, IsraelThoracic Cancer Service, Rambam Health Care Campus, Haifa, IsraelInstitute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, IsraelInstitute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, IsraelInstitute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, IsraelThoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, IsraelThoracic Cancer Service, Rambam Health Care Campus, Haifa, IsraelBackground Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC).Methods 125 consecutive patients with aLCNEC were identified in the electronic databases of 4 participating cancer centers. The patients were divided into group A (patients who received ICI, n=41) and group B (patients who did not receive ICI, n=84). Overall survival since advanced disease diagnosis (OS DX) and OS since ICI initiation (OS ICI) were captured.Results With a median follow-up of 11.8 months (mo) (IQR 7.5–17.9) and 6.0mo (IQR 3.1–10.9), 66% and 76% of patients died in groups A and B, respectively. Median OS DX was 12.4mo (95% CI 10.7 to 23.4) and 6.0mo (95% CI 4.7 to 9.4) in groups A and B, respectively (log-rank test, p=0.02). For ICI administration, HR for OS DX was 0.59 (95% CI 0.38 to 0.93, p=0.02—unadjusted), and 0.58 (95% CI 0.34 to 0.98, p=0.04—adjusted for age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), presence of liver metastases and chemotherapy administration). In a propensity score matching analysis (n=74; 37 patients in each group matched for age and ECOG PS), median OS DX was 12.5 mo (95% CI 10.6 to 25.2) and 8.4 mo (95% CI 5.4 to 16.9) in matched groups A and B, respectively (log-rank test, p=0.046). OS ICI for patients receiving ICI as monotherapy (n=36) was 11.0 mo (95% CI 6.1 to 19.4).Conclusions With the limitations of retrospective design and small sample size, the results of this real-world cohort analysis suggest a positive impact of ICI on OS in aLCNEC.https://jitc.bmj.com/content/9/2/e001999.full |
| spellingShingle | Samuel Kareff Jair Bar Amir Onn Alona Zer Chul Kim Stephen V Liu Elizabeth Dudnik Mor Moskovitz Anastasiya Lobachov Teodor Gottfried Damien Urban Ofer Rotem Mira Wollner Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung Journal for ImmunoTherapy of Cancer |
| title | Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung |
| title_full | Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung |
| title_fullStr | Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung |
| title_full_unstemmed | Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung |
| title_short | Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung |
| title_sort | real world survival outcomes with immune checkpoint inhibitors in large cell neuroendocrine tumors of lung |
| url | https://jitc.bmj.com/content/9/2/e001999.full |
| work_keys_str_mv | AT samuelkareff realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT jairbar realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT amironn realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT alonazer realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT chulkim realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT stephenvliu realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT elizabethdudnik realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT mormoskovitz realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT anastasiyalobachov realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT teodorgottfried realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT damienurban realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT oferrotem realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung AT mirawollner realworldsurvivaloutcomeswithimmunecheckpointinhibitorsinlargecellneuroendocrinetumorsoflung |